ERBB2 and breast cancer: Analysis from The Cancer Genome Atlas (TCGA) supported this notion by demonstrating TNBCs and HER2+ breast cancers exhibit increased immune metagene expression compared to those of the ER+ subtype (Safonov et al., 2017).